🏛️ Verified NIH Record • Updated 2025-12-19
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (NCT03997123)
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC.
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca
🩺 Plain-English Summary (8th-Grade Level)
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
Who can join: Review the eligibility criteria below.
Location: Research Site — Whittier, California
Age range: 18 Years to 130 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (260 Sites)
Showing the first 25 of 260 sites.
- Research Site — Whittier, California
- Research Site — Whittier, California
- Research Site — Fort Myers, Florida
- Research Site — Miami, Florida
- Research Site — St. Petersburg, Florida
- Research Site — Tampa, Florida
- Research Site — Chicago, Illinois
- Research Site — Westwood, Kansas
- Research Site — Silver Spring, Maryland
- Research Site — Detroit, Michigan
- Research Site — Nyack, New York
- Research Site — Cincinnati, Ohio
- Research Site — Columbus, Ohio
- Research Site — Harrisburg, Pennsylvania
- Research Site — Philadelphia, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Nashville, Tennessee
- Research Site — Austin, Texas
- Research Site — Fort Worth, Texas
- Research Site — Houston, Texas
- Research Site — San Antonio, Texas
- Research Site — Fairfax, Virginia
- Research Site — Buenos Aires,
- Research Site — CABA,
- Research Site — CABA,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Triple Negative Breast Neoplasms
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer — Tucson, Arizona
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) — Mobile, Alabama
Explore by condition: All Triple Negative Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.